

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANT(S): Anderson et al.
SERIAL NUMBER: 10/052,648 EXAMINER: Not Yet Assigned
FILING DATE: January 18, 2002 ART UNIT: 1614
FOR: Novel Human Proteins And Nucleic Acids Encoding Same

Box IDS

Assistant Commissioner for Patents
Washington, D.C. 20231



30623

PATENT TRADEMARK OFFICE

TRANSMITTAL LETTER

Transmitted herewith for filing in the present application are the following documents:

1. Information Disclosure Statement (2 pages), in duplicate;
2. Modified Form 1449/PTO (4 pages) in duplicate;
3. Copies of cited references B1-B2 and C1-C98; and
4. Return Postcard

No fee is believed to be due at this time. However, the Commissioner is authorized to charge any fees that may be due to Deposit Account No. 50-0311, Reference No. 21402-250 (CURA-550). A duplicate copy of this transmittal letter is enclosed.

If the enclosed papers are considered incomplete, the Mail Room and/or the Application Branch is respectfully requested to contact the undersigned at 617/542-6000, Boston, Massachusetts.

Respectfully submitted,


Matthew J. Golden (Reg. No. 35,161)
Attorney for Applicants

c/o MINTZ, LEVIN, COHN, FERRIS
GLOVSKY AND POPEO, P.C.

One Financial Center
Boston, MA 02111
Tel: (617) 542-6000
Fax: (617) 542-2241

July 15, 2002

Date of Deposit: July 15, 2002



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANT(S): Anderson et al.


SERIAL NO.: 10/052,648

EXAMINER: Not Yet Assigned

FILING DATE: January 18, 2002

ART UNIT: 1614

FOR: Novel Human Proteins And Nucleic Acids Encoding Same



Box IDS

Assistant Commissioner for Patents
Washington, D.C. 20231

INFORMATION DISCLOSURE STATEMENT


Pursuant to the duty of disclosure under 37 C.F.R. §§1.56, 1.97 and 1.98, Applicants hereby make of record the documents listed below and on the attached modified Form PTO-1449 (submitted in duplicate) in the above-identified application. The order of presentation of the references should not be construed as an indication of the importance of the references. This Information Disclosure Statement is being filed before the mailing date of a first Office Action on the merits in the above-identified case. Accordingly, no fee or certification is required. 37 C.F.R. §1.97.

A copy of each of the references is enclosed unless otherwise indicated on the attached Form PTO-1449 (modified). It is respectfully requested that the Examiner consider completely the cited information, along with any other information, in reaching a determination concerning the patentability of the present claims, and signs the enclosed form PTO-1449 to evidence that the cited information has been fully considered by the Patent and Trademark Office during the examination of this application.

By submitting this Information Disclosure Statement, the Applicant makes no representation that: (1) a search has been performed, of the extent of any search performed, or that more relevant information does not exist; (2) the information cited in the Statement is, or is considered to be, material to patentability as defined in 37 C.F.R. §1.56(b); and (3) the information cited in the Statement is, or is considered to be, in fact, prior art as defined by 35 U.S.C. §102.

Notwithstanding any statements by the Applicant, the Examiner is urged to form his/her own conclusion regarding the relevance of the cited information. An early and favorable action is hereby requested. Please charge any fees that may be due, or credit any overpayment of same, to Deposit Account No. 50-0311 Reference No. 21402-250 (CURA-550).

Respectfully submitted,

A handwritten signature in black ink, appearing to read "Matthew J. Golden", written over a horizontal line.

Matthew J. Golden (Reg. No. 35,161)
Attorney for Applicants

c/o MINTZ, LEVIN, COHN, FERRIS
GLOVSKY AND POPEO, P.C.

One Financial Center
Boston, MA 02111
Tel: (617) 542-6000
Fax: (617) 542-2241

Dated: July 15, 2002

NYC 240530v1

Express Mail No. EL752689899US

Date of Deposit: July 15, 2002

RECEIVED Page 1 of 4

JUL 19 2002

Please type a plus sign (+) in this box

+

TECH CENTER 1600/2900
Patent and Trademark Office, U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Modified Form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)	Application Number	10/052,648
	Filing Date	1/18/02
	First Named Inventor	Anderson
	Group Art Unit	1614
	Examiner Name	Not Yet Assigned
	Attorney Docket Number	21402-250 (CURA-550)

U.S. PATENT DOCUMENTS							
Exam Initials	Cite No.	U.S. Patent Document No.	Issue Date	Name of Patentee(s) or Applicant(s)	Class	Sub Class	Filing Date If Appropriate

FOREIGN PATENT DOCUMENTS							
Exam Initials	Cite No.	Foreign Patent Document Office	Number	Name of Patentee(s) or Applicant(s)	Date of Publication	Translation Yes	No
	B1	WO	01/02568	Chiron Corporation (page 1 of 1046 ONLY)	1/11/2001		
	B2	WO	99/67282	Centre National de la Reserche Scientifique	12/29/1999		

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS		
Exam Initials	Cite No.	Name of Author, Title (when appropriate), Publication, Volume, Page(s), Date, Etc.
	C1	Alessi, D. R., C. Smythe, et al. (1993). "The human CL100 gene encodes a Tyr/Thr-protein phosphatase which potently and specifically inactivates MAP kinase and suppresses its activation by oncogenic ras in Xenopus oocyte extracts." Oncogene 8(7): 2015-20.
	C2	Blier, P. (2001). "Pharmacology of rapid-onset antidepressant treatment strategies." J Clin Psychiatry 62(Suppl 15): 12-7.
	C3	Boschert, U., M. Muda, et al. (1997). "Induction of the dual specificity phosphatase PAC1 in rat brain following seizure activity." Neuroreport 8(14): 3077-80.
	C4	Brondello, J. M., J. Pouyssegur, et al. (1999). "Reduced MAP kinase phosphatase-1 degradation after p42/p44MAPK- dependent phosphorylation." Science 286(5449): 2514-7.
	C5	El Yacoubi, M., C. Ledent, et al. (2001). "Adenosine A2A receptor antagonists are potential antidepressants: evidence based on pharmacology and A2A receptor knockout mice." Br J Pharmacol 134(1): 68-77.
	C6	GenBank Accession Number: AAD55304 (16-SEP-1999)
	C7	GenBank Accession Number: AAF24125 (12-JAN-2000)
	C8	GenBank Accession Number: AAF31483 (08-FEB-2000)
	C9	GenBank Accession Number: AAF74258 (06-JUN-2000)
	C10	GenBank Accession Number: AAH04110 (12-JUL-2001)
	C11	GenBank Accession Number: AAH20036 (22-JAN-2002)
	C12	GenBank Accession Number: AAK17190 (17-SEP-2001)
	C13	GenBank Accession Number: AAK91995 (19-AUG-2001)
	C14	GenBank Accession Number: AAL33583 (20-NOV-2001)
	C15	GenBank Accession Number: AAL38571 (06-DEC-2001)
	C16	GenBank Accession Number: AAL55862 (01-JAN-2002)
	C17	GenBank Accession Number: AAL55880 (01-JAN-2002)



Express Mail N . EL752689899US

Date of Deposit: July 15, 2002

Page 3 of 4

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS

Exam Initials	Cite No.	Name of Author, Title (when appropriate), Publication, Volume, Page(s), Date, Etc.
	C61	GenBank Accession Number: NM_019833 (07-JAN-2002)
	C62	GenBank Accession Number: NM_030903 (14-APR-2001)
	C63	GenBank Accession Number: NM_032387 (02-NOV-2001)
	C64	GenBank Accession Number: NM_032446 (24-MAY-2001)
	C65	GenBank Accession Number: NM_053794 (07-NOV-2001)
	C66	GenBank Accession Number: NP_037407 (10-DEC-2001)
	C67	GenBank Accession Number: NP_056023 (10-DEC-2001)
	C68	GenBank Accession Number: NP_061852 (01-SEP-2001)
	C69	GenBank Accession Number: NP_062807 (07-JAN-2002)
	C70	GenBank Accession Number: NP_112165 (14-APR-2001)
	C71	GenBank Accession Number: NP_115763 (02-NOV-2001)
	C72	GenBank Accession Number: NP_115822 (24-MAY-2001)
	C73	GenBank Accession Number: NP_446246 (07-NOV-2001)
	C74	GenBank Accession Number: XM_028387 (07-FEB-2002)
	C75	GenBank Accession Number: XM_030163 (06-FEB-2002)
	C76	GenBank Accession Number: XM_038481 (07-FEB-2002)
	C77	GenBank Accession Number: XM_060558 (06-FEB-2002)
	C78	GenBank Accession Number: XM_065820 (06-FEB-2002)
	C79	GenBank Accession Number: XM_066736 (07-FEB-2002)
	C80	GenBank Accession Number: XM_066756 (07-FEB-2002)
	C81	GenBank Accession Number: XP_028387 (07-FEB-2002)
	C82	GenBank Accession Number: XP_030163 (06-FEB-2002)
	C83	GenBank Accession Number: XP_038481 (07-FEB-2002)
	C84	GenBank Accession Number: XP_060558 (06-FEB-2002)
	C85	GenBank Accession Number: XP_065820 (06-FEB-2002)
	C86	GenBank Accession Number: XP_066736 (07-FEB-2002)
	C87	GenBank Accession Number: XP_066756 (07-FEB-2002)
	C88	Heinemann, A., A. Hartnell, et al. (2000). "Basophil responses to chemokines are regulated by both sequential and cooperative receptor signaling." J Immunol 165(12): 7224-33.
	C89	Jiang, R., Y. Lan, et al. (1998). "Defects in limb, craniofacial, and thymic development in Jagged2 mutant mice." Genes Dev 12(7): 1046-57.
	C90	Keyse, S. M. and E. A. Emslie (1992). "Oxidative stress and heat shock induce a human gene encoding a protein- tyrosine phosphatase." Nature 359(6396): 644-7.
	C91	Lanford, P. J., Y. Lan, et al. (1999). "Notch signalling pathway mediates hair cell development in mammalian cochlea." Nat Genet 21(3): 289-92.
	C92	Luo, B., J. C. Aster, et al. (1997). "Isolation and functional analysis of a cDNA for human Jagged2, a gene encoding a ligand for the Notch1 receptor." Mol Cell Biol 17(10): 6057-67.
	C93	Monopoli, A., G. Lozza, et al. (1998). "Blockade of adenosine A2A receptors by SCH 58261 results in neuroprotective effects in cerebral ischaemia in rats." Neuroreport 9(17): 3955-9.
	C94	Muda, M., U. Boschert, et al. (1996). "MKP-3, a novel cytosolic protein-tyrosine phosphatase that exemplifies a new class of mitogen-activated protein kinase phosphatase." J Biol Chem 271(8): 4319-26.
	C95	Pittenger, M. F., A. M. Mackay, et al. (1999). "Multilineage potential of adult human mesenchymal stem cells." Science 284(5411): 143-7.
	C96	Shutter, J. R., S. Scully, et al. (2000). "DII4, a novel Notch ligand expressed in arterial endothelium."

RECEIVED
JUL 19 2002
TECH CENTER 1600/2900

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS


Sam Initials	Cite No.	Name of Author, Title (when appropriate), Publication, Volume, Page(s), Date, Etc.
	C18	GenBank Accession Number: AB011532 (22-AUG-1998)
	C19	GenBank Accession Number: AB020681 (16-JUN-1999)
	C20	GenBank Accession Number: AB030186 (29-MAR-2000)
	C21	GenBank Accession Number: AB044546 (30-MAR-2001)
	C22	GenBank Accession Number: AB058676 (10-MAY-2001)
	C23	GenBank Accession Number: AF044033 (16-SEP-1999)
	C24	GenBank Accession Number: AF061944 (08-FEB-2000)
	C25	GenBank Accession Number: AF098664 (26-MAR-1999)
	C26	GenBank Accession Number: AF120032 (03-JAN-2001)
	C27	GenBank Accession Number: AF121775 (12-JAN-2000)
	C28	GenBank Accession Number: AF168676 (01-AUG-2000)
	C29	GenBank Accession Number: AF227741 (06-JUN-2000)
	C30	GenBank Accession Number: AF317425 (07-DEC-2000)
	C31	GenBank Accession Number: AF318355 (01-JAN-2002)
	C32	GenBank Accession Number: AF318373 (01-JAN-2002)
	C33	GenBank Accession Number: AF332189 (17-SEP-2001)
	C34	GenBank Accession Number: AF390018 (19-AUG-2001)
	C35	GenBank Accession Number: AF440279 (20-NOV-2001)
	C36	GenBank Accession Number: AF444274 (06-DEC-2001)
	C37	GenBank Accession Number: AJ296290 (23-JAN-2002)
	C38	GenBank Accession Number: AJ302602 (06-JAN-2001)
	C39	GenBank Accession Number: AJ302603 (06-JAN-2001)
	C40	GenBank Accession Number: AJ316534 (23-JAN-2002)
	C41	GenBank Accession Number: AK007061 (19-JAN-2002)
	C42	GenBank Accession Number: AK013580 (19-JAN-2002)
	C43	GenBank Accession Number: AK025523 (29-SEP-2000)
	C44	GenBank Accession Number: AL133545 (10-NOV-2000)
	C45	GenBank Accession Number: AX008326 (06-SEP-2000)
	C46	GenBank Accession Number: AX071876 (25-JAN-2001)
	C47	GenBank Accession Number: BAA74897 (16-JUN-1999)
	C48	GenBank Accession Number: BAB24847 (19-JAN-2002)
	C49	GenBank Accession Number: BAB28914 (19-JAN-2002)
	C50	GenBank Accession Number: BAB47409 (10-MAY-2001)
	C51	GenBank Accession Number: BC004110 (12-JUL-2001)
	C52	GenBank Accession Number: BC020036 (22-JAN-2002)
	C53	GenBank Accession Number: CAC10195 (10-NOV-2000)
	C54	GenBank Accession Number: CAC15059 (23-JAN-2002)
	C55	GenBank Accession Number: CAC20522 (06-JAN-2001)
	C56	GenBank Accession Number: CAC20523 (06-JAN-2001)
	C57	GenBank Accession Number: CAC48387 (23-JAN-2002)
	C58	GenBank Accession Number: NM_013275 (10-DEC-2001)
	C59	GenBank Accession Number: NM_015208 (10-DEC-2001)
	C60	GenBank Accession Number: NM_018979 (01-SEP-2001)

RECEIVED

JUL 19 2002

TECH CENTER 1600/2900





Express Mail N . EL752689899US

Date of Deposit: July 15, 2002

RECEIVED
Page 4 of 4
JUL 19 2002

TECH CENTER 1600/2900

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS

Exam No.	Cite No.	Name of Author, Title (when appropriate), Publication, Volume, Page(s), Date, Etc.
		Genes Dev 14(11): 1313-8.
	C97	Tranquillini, M. E. and A. Reggiani (1999). "Glycine-site antagonists and stroke." Expert Opin Investig Drugs 8(11): 1837-1848. ABSTRACT ONLY
	C98	Wiessner, C. (1995). "The dual specificity phosphatase PAC-1 is transcriptionally induced in the rat brain following transient forebrain ischemia." Mol Brain Res 28(2): 353-6.

* a copy of this reference is not provided as it was previously cited by or submitted to the office in a prior application, Serial No. _____, filed _____, and relied upon for an earlier filing date under 35 U.S.C. §120 (continuation, continuation-in-part, and divisional applications).

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered.

Include copy of this form with next communication to applicant.